Gilead Sciences (GILD) Other Non-Current Assets (2009 - 2026)

Gilead Sciences (GILD) reported Other Non-Current Assets of $4.6 billion for Q1 2026, up 17.64% on a YoY basis from $3.9 billion in Q1 2025, and down 6.01% quarter-over-quarter from $4.8 billion in Q4 2025.

Gilead Sciences (GILD) Other Non-Current Assets (2009 - 2026) Analysis & Trends

Gilead Sciences has reported Other Non-Current Assets for 18 years, with the latest figure at $4.6 billion in Q1 2026.

  • For the quarter ending Q1 2026, Other Non-Current Assets rose 17.64% year-over-year to $4.6 billion; the trailing twelve-month figure through Mar 2026 stood at $4.6 billion (up 17.64% YoY), and the FY2025 full-year result was $4.8 billion, up 28.55% from the prior year.
  • Other Non-Current Assets for Q1 2026 stood at $4.6 billion, down from $4.8 billion in the prior quarter.
  • The five-year high for Other Non-Current Assets was $5.5 billion in Q3 2024, with the low at $3.8 billion in Q4 2024.
  • Historically, Other Non-Current Assets has averaged $4.7 billion across 5 years, with a median of $4.8 billion in 2022.
  • Annual changes were most pronounced in 2024 — Other Non-Current Assets surged 30.81% — and 2025, when it fell 25.39%.
  • Gilead Sciences' Other Non-Current Assets stood at $4.8 billion in 2022, then dropped by 0.17% to $4.8 billion in 2023, then dropped by 21.35% to $3.8 billion in 2024, then climbed by 28.55% to $4.8 billion in 2025, then declined by 6.01% to $4.6 billion in 2026.
  • The last three Other Non-Current Assets figures came in at $4.6 billion (Q1 2026), $4.8 billion (Q4 2025), and $4.9 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn 3.18 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn 7.23 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn 14.11 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn 10.54 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn 19.81 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn 12.76 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 4.55 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn 9.83 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn 6.08 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn - 200.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 4.55 Bn
Dec 31, 2025 4.85 Bn
Sep 30, 2025 4.87 Bn
Jun 30, 2025 4.03 Bn
Mar 31, 2025 3.87 Bn
Dec 31, 2024 3.77 Bn
Sep 30, 2024 5.49 Bn
Jun 30, 2024 4.77 Bn
Mar 31, 2024 5.19 Bn
Dec 31, 2023 4.79 Bn
Sep 30, 2023 4.20 Bn
Jun 30, 2023 5.11 Bn
Mar 31, 2023 4.95 Bn
Dec 31, 2022 4.80 Bn
Sep 30, 2022 4.62 Bn
Jun 30, 2022 4.86 Bn
Mar 31, 2022 5.13 Bn
Dec 31, 2021 4.96 Bn
Sep 30, 2021 4.74 Bn
Jun 30, 2021 5.55 Bn